Clinical Trial Update: Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of CTAP101 (calcifediol) ER capsules for secondary hyperparathyroidism in h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperparathyroidism
• Vitamin Deficiency

Drugs mentioned

• CTAP101 (Calcifediol) ER Capsules (calcifediol extended-release capsule)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases | Phase 2 | Status: TERMINATED | Results posted: 2025-03-30